Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2010

View Archived Issues

3SBio and Panacor sign agreement to develop and commercialize Nephoxil in China

Ticagrelor better option than clopidogrel in patients with acute coronary syndromes

FYO-750 improves bladder capacity in neurogenic detrusor overactivity in rats

Tamoxifen plus chemotherapy beneficial in postmenopausal breast cancer patients

The CXCR1antagonist repertaxin targets breast cancer stem cells in vivo

New LXRbeta agonists discovered by Kowa

Concert Pharmaceuticals describes novel DPP-IV inhibitors

Trigemina begins phase IIa oxytocin trial in chronic daily headache

Bristol-Myers Squibb reports the discovery of novel MCH-R1 antagonists

Wyeth identifies novel 5-HT6 receptor ligands

CRUK to fund trial of Advaxis' HPV vaccine in head and neck cancer

Cancer Research Technology claims novel dual CYP26 inhibitors/RAMBAs

QR Pharma initiates Posiphen trial in cognitively impaired patients

Phase I trial commences for NPC-1C in pancreatic and colorectal cancer

Biovail and Alexza to commercialize and develop AZ-004 for multiple indications

ReNeuron receives approval for landmark trial of ReN-001 stem cell therapy in stroke

Novartis describes identification of compounds targeting PI3K

Phase III mipomersen study meets primary endpoint in heFH

Naurex reports topline phase I results on GLYX-13 for depression

Vertex reports full-year 2009 R&D highlights

Tekmira presents update on its activities for 2010

FDA approves AstraZeneca's Crestor for heart disease

4SC begins dosing in first-in-man phase I trial of 4SC-205 in cancer

Intercell reports phase I results of S. pneumoniae vaccine IC-47

Roche reports positive results from phase III clinical program of taspoglutide in diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...